Abergel A

1 publications in the catalogue · 2020–2020 · 1 as first author

1 publications

Product

Diseases

Co-authors

  1. Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.

    Abergel A et al. · Liver Int · 2020

    FibroTest HCV